Based on these observations, our bispecific Iren-AuSiO2_CL4_Gint4.T nanoparticles could be safely applied not only to breast cancer PDO, as in the present study, but also several others EGFR-expressing cancers. At the same time, the proposed strategy for aptamer-functionalized nanoformulation can be easily adapted to different targets by switching the aptamers for other malignant tumors. The gene discussed is EGFR; the disease is breast cancer.